Medtronic (NYSE:MDT) announced that it received a license from Health Canada for use of its Guardian 4 with the MiniMed 780G.
The licensing enables the use of the next-generation continuous glucose monitor sensor with the next-generation automated insulin pump. MiniMed 780G with Guardian 4, an advanced, hybrid closed-loop system, helps users manage type 1 diabetes.
Health Canada licensing comes on the heels of FDA approval for the MiniMed 780G with Guardian 4. The system requires no fingersticks while in SmartGuard mode. It offers meal detection technology, providing automatic adjustments and corrections to sugar levels every five minutes. This occurs for both basal (background) and bolus (mealtime) insulin needs.
MiniMed 780G with Guardian 4 offers insulin to account for when users forget to bolus or underestimate the number of carbs in their meal.
Medtronic expects to launch the new sensor in Canada by the end of 2023. Canadian officials previously approved the MiniMed 780G pump in November 2022.
“With the recent launch of the world’s first and only insulin pump system with meal detection technology, we are hearing from our MiniMed 780G system users that it’s helping increase their time in range and the improved usability of our system is already making a significant impact on their day-to-day lives,” said Laura Cameron, senior director of endocrinology at Medtronic Canada. “We’re thrilled to expand our innovative solutions that help simplify diabetes management with the goal of making lives easier for those we have the privilege to support.”
Que Dallara, Medtronic Diabetes EVP and president, and Ali Dianaty, VP of product innovation, spoke with Drug Delivery Business News following the system’s FDA approval. Read about it here.